Conference Coverage
Conference Coverage
New Survey Explores New Daily Persistent Headache
Patient responses suggest CGRP inhibitors might be a good preventative, and that many experience brain fog.
Conference Coverage
Shift Needed in Research, Treatment, Care for Aging MS Population
Independent of disease progression, the impact of aging on MS has been underappreciated in research and in clinical practice.
Conference Coverage
Why Don’t Migraine Patients Seek Treatment?
Participants cited concerns that their complaints would be dismissed, a belief that healthcare providers could offer no additional help, and a...
Conference Coverage
One Patient Changed This Oncologist’s View of Hope. Here’s How.
“How we think about hope directly influences patient care,” according to a professor of clinical medicine at Weill Cornell Medicine in New York...
Conference Coverage
Lidocaine Effective Against Pediatric Migraine
The first randomized, controlled trial confirms observational studies and could pave the way for insurance coverage.
Conference Coverage
Anticoagulation Shows No Benefit in Preventing Second Stroke
Oral anticoagulation with edoxaban did not reduce risk for a second stroke and the risk for major bleeding was more than quadruple the risk with...
Conference Coverage
Potential Genes Identified for Post-Traumatic Headache
Findings could point the way to screening youth for vulnerability to head trauma.
Conference Coverage
Measuring Cognition in Migraine, One Patient at a Time
Researchers are developing intensive testing methods to better understand cognitive function in different migraine phases.
Conference Coverage
Upadacitinib Proves Successful in First JAK Inhibitor Trial for Giant Cell Arteritis
Results from the SELECT-GCA study showed that upadacitinib (Rinvoq) induced significant and sustained remission in people with new-onset or...
Conference Coverage
Prospective MS Trial Proves Ocrelizumab Efficacy in Under-Represented Populations
A prospective phase 4 clinical trial that recruited solely Black and Hispanic patients could shed light on divergent treatment outcomes.
Conference Coverage
Pediatric Ocrelizumab Dose Established for MS
Pharmacokinetic and pharmacodynamic data show that adult dose is safe and effective for most children.